FMS-like Tyrosine Kinase 3 Inhibitors Pipeline Market Research Report 2022: Insights on Approx 25+ Companies and 25+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “FMS-like tyrosine kinase 3 inhibitors – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “FMS-like tyrosine kinase 3 inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the FMS-like tyrosine kinase 3 inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence FMS-like tyrosine kinase 3 inhibitors R&D. The therapies under development are focused on novel approaches for FMS-like tyrosine kinase 3 inhibitors.

FMS-like tyrosine kinase 3 inhibitors Emerging Drugs Chapters

This segment of the FMS-like tyrosine kinase 3 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

FMS-like tyrosine kinase 3 inhibitors Emerging Drugs

CG-806: Aptose Biosciences

CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor. This small molecule, in-licensed from CrystalGenomics in Seoul, South Korea, demonstrates potent inhibition of wild type and all mutant forms of FLT3 (including internal tandem duplication, or ITD, and mutations of the receptor tyrosine kinase domain and gatekeeper region), cures animals of acute myeloid leukemia (AML) tumors in the absence of toxicity in murine xenograft models. The drug is in Phase I/II clinical studies for the treatment of CLL & NHL.

Quizartinib: Daiichi Sankyo Company

Quizartinib is an orally administered, small molecule FLT3 kinase inhibitor. Quizartinib was approved by the Ministry of Health, Labor and Welfare (MHLW) of Japan under the brand name of VANFLYTA for the treatment of adult patients with relapsed/refractory FLT3-ITD AML on June 18, 2019. Quizartinib is currently being studied alone or in combination with other agents as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in adult and pediatric populations.

Major Players working on FMS-like tyrosine kinase 3 inhibitors

There are approx. 25+ key companies which are developing the FMS-like tyrosine kinase 3 inhibitors. The companies which have their FMS-like tyrosine kinase 3 inhibitors drug candidates in the most advanced stage, i.e. Phase III, include Quizartinib.

Key Players

• Aptose Biosciences
• Daiichi Sankyo Company
• Celon Pharma
• AROG Pharmaceuticals
• Pfizer
• Ascentage Pharma
• Pharos I&BT Co
• Novartis Oncology
• Exelixis
• Ipsen

Key Products

• CG-806
• Quizartinib

Research program: small molecule anti-cancer therapeutics

• Crenolanib
• Olverembatinib
• PHI-101
• Midostaurin
• Cabozantinib

Key Topics Covered:

Introduction

Executive Summary

FMS-like tyrosine kinase 3 inhibitors: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

FMS-like tyrosine kinase 3 inhibitors – Analytical Perspective

In-depth Commercial Assessment

• FMS-like tyrosine kinase 3 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

FMS-like tyrosine kinase 3 inhibitors Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Quizartinib: Daiichi Sankyo Company

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Coltuximab Ravtansine: Sanofi

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

CG-806: Aptose Biosciences

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

RC58: RemeGen

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

FMS-like tyrosine kinase 3 inhibitors Key Companies

FMS-like tyrosine kinase 3 inhibitors Key Products

FMS-like tyrosine kinase 3 inhibitors – Unmet Needs

FMS-like tyrosine kinase 3 inhibitors – Market Drivers and Barriers

FMS-like tyrosine kinase 3 inhibitors – Future Perspectives and Conclusion

FMS-like tyrosine kinase 3 inhibitors Analyst Views

FMS-like tyrosine kinase 3 inhibitors Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7xsiwj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900